Please assess the completion status of the following clinical trial:

Trial Title: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* positive Hepatitis B surface antigen (HBsAg) for \>6 months, positive HBeAg, HBV DNA \>500,000 copies/mL, and anti-HBs negative;~* liver disease consistent with Chronic Hepatitis B.~Exclusion Criteria:~* antiviral therapy for CHB within previous 6 months;~* co-infection with Hepatitis A virus (HAV), Hepatitis C virus (HCV), Hepatitis D virus (HDV) or Human immuno deficiency virus (HIV);~* evidence of decompensated liver disease;~* medical condition associated with chronic liver disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- peginterferon alfa-2a 90 μg_24 Weeks (Type: EXPERIMENTAL): Participants received 90 micrograms (μg) peginterferon alfa-2a subcutaneous once a week for 24 weeks.
- peginterferon alfa-2a 180 μg_24 Weeks (Type: EXPERIMENTAL): Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 24 weeks.
- peginterferon alfa-2a 90 μg_48 Weeks (Type: EXPERIMENTAL): Participants received 90 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.
- peginterferon alfa-2a 180 μg_48 Weeks (Type: EXPERIMENTAL): Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).